Literature DB >> 33407730

Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells.

Yu Shi1, Liankang Sun2, Rui Zhang2, Yuan Hu1, Yinying Wu1, Xuyuan Dong1, Danfeng Dong1, Chen Chen2, Zhimin Geng2, Enxiao Li3, Yangwei Fan4.   

Abstract

BACKGROUND: Cancer-associated fibroblasts (CAFs), the primary component of tumor stroma in tumor microenvironments, are well-known contributors to the malignant progression of gallbladder cancer (GBC). Thrombospondins (THBSs or TSPs) comprise a family of five adhesive glycoproteins that are overexpressed in many types of cancers. However, the expression and potential roles of TSPs in the crosstalk between CAFs and GBC cells has remained unclear.
METHODS: Peritumoral fibroblasts (PTFs) and CAFs were extracted from GBC tissues. Thrombospondin expression in GBC was screened by RT-qPCR. MTT viability assay, colony formation, EdU incorporation assay, flow cytometry analysis, Transwell assay, tumorsphere formation and western blot assays were performed to investigate the effects of CAF-derived TSP-4 on GBC cell proliferation, EMT and cancer stem-like features. Subcutaneous tumor formation models were established by co-implanting CAFs and GBC cells or GBC cells overexpressing heat shock factor 1 (HSF1) to evaluate the roles of TSP-4 and HSF1 in vivo. To characterize the mechanism by which TSP-4 is involved in the crosstalk between CAFs and GBC cells, the levels of a variety of signaling molecules were detected by coimmunoprecipitation, immunofluorescence staining, and ELISA assays.
RESULTS: In the present study, we showed that TSP-4, as the stromal glycoprotein, is highly expressed in CAFs from GBC and that CAF-derived TSP-4 induces the proliferation, EMT and cancer stem-like features of GBC cells. Mechanistically, CAF-secreted TSP-4 binds to the transmembrane receptor integrin α2 on GBC cells to induce the phosphorylation of HSF1 at S326 and maintain the malignant phenotypes of GBC cells. Moreover, the TSP-4/integrin α2 axis-induced phosphorylation of HSF1 at S326 is mediated by Akt activation (p-Akt at S473) in GBC cells. In addition, activated HSF1 signaling increased the expression and paracrine signaling of TGF-β1 to induce the transdifferentiation of PTFs into CAFs, leading to their recruitment into GBC and increased TSP-4 expression in CAFs, thereby forming a positive feedback loop to drive the malignant progression of GBC.
CONCLUSIONS: Our data indicate that a complex TSP-4/integrin α2/HSF1/TGF-β cascade mediates reciprocal interactions between GBC cells and CAFs, providing a promising therapeutic target for gallbladder cancer patients.

Entities:  

Keywords:  Cancer stemness; Cancer-associated fibroblasts; Gallbladder cancer; Heat shock factor 1; Proliferation; Thrombospondin 4

Year:  2021        PMID: 33407730     DOI: 10.1186/s13046-020-01812-7

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  47 in total

Review 1.  Extracellular matrix component signaling in cancer.

Authors:  Hinke A B Multhaupt; Birgit Leitinger; Donald Gullberg; John R Couchman
Journal:  Adv Drug Deliv Rev       Date:  2015-10-28       Impact factor: 15.470

Review 2.  Gallbladder cancer: past, present and an uncertain future.

Authors:  C Boutros; M Gary; K Baldwin; P Somasundar
Journal:  Surg Oncol       Date:  2012-09-29       Impact factor: 3.279

3.  CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness.

Authors:  Shicheng Su; Jianing Chen; Herui Yao; Jiang Liu; Shubin Yu; Liyan Lao; Minghui Wang; Manli Luo; Yue Xing; Fei Chen; Di Huang; Jinghua Zhao; Linbin Yang; Dan Liao; Fengxi Su; Mengfeng Li; Qiang Liu; Erwei Song
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

4.  Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.

Authors:  Maolan Li; Zhou Zhang; Xiaoguang Li; Junyi Ye; Xiangsong Wu; Zhujun Tan; Chang Liu; Baiyong Shen; Xu-An Wang; Wenguang Wu; Daizhan Zhou; Di Zhang; Ting Wang; Bingya Liu; Kai Qu; Qichen Ding; Hao Weng; Qian Ding; Jiasheng Mu; Yijun Shu; Runfa Bao; Yang Cao; Peizhan Chen; Tianyu Liu; Lin Jiang; Yunping Hu; Ping Dong; Jun Gu; Wei Lu; Weibin Shi; Jianhua Lu; Wei Gong; Zhaohui Tang; Yong Zhang; Xuefeng Wang; Y Eugene Chin; Xiaoling Weng; Hong Zhang; Wei Tang; Yonglan Zheng; Lin He; Hui Wang; Yun Liu; Yingbin Liu
Journal:  Nat Genet       Date:  2014-07-06       Impact factor: 38.330

Review 5.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 6.  The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas.

Authors:  Yoshihiro Mezawa; Akira Orimo
Journal:  Cell Tissue Res       Date:  2016-08-10       Impact factor: 5.249

7.  Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling.

Authors:  Wan-Jiun Chen; Chao-Chi Ho; Yih-Leong Chang; Hsuan-Yu Chen; Chih-An Lin; Thai-Yen Ling; Sung-Liang Yu; Shin-Sheng Yuan; Yu-Ju Louisa Chen; Chien-Yu Lin; Szu-Hua Pan; Han-Yi Elizabeth Chou; Yu-Ju Chen; Gee-Chen Chang; Wen-Cheng Chu; Yee-Ming Lee; Jen-Yi Lee; Pei-Jung Lee; Ker-Chau Li; Huei-Wen Chen; Pan-Chyr Yang
Journal:  Nat Commun       Date:  2014-03-25       Impact factor: 14.919

Review 8.  Origins of metastatic traits.

Authors:  Sakari Vanharanta; Joan Massagué
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

9.  MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7.

Authors:  Yuan-Yuan Ye; Jia-Wei Mei; Shan-Shan Xiang; Huai-Feng Li; Qiang Ma; Xiao-Ling Song; Zheng Wang; Yi-Chi Zhang; Yong-Chen Liu; Yun-Peng Jin; Yun-Ping Hu; Lin Jiang; Fa-Tao Liu; Yi-Jian Zhang; Ya-Juan Hao; Ying-Bin Liu
Journal:  Cell Death Dis       Date:  2018-03-14       Impact factor: 8.469

Review 10.  Stem cell programs in cancer initiation, progression, and therapy resistance.

Authors:  Tianzhi Huang; Xiao Song; Dandan Xu; Deanna Tiek; Anshika Goenka; Bingli Wu; Namratha Sastry; Bo Hu; Shi-Yuan Cheng
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

View more
  6 in total

1.  Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer.

Authors:  Junki Harada; Yasuyoshi Miyata; Kyohei Araki; Tsuyoshi Matsuda; Yoshiaki Nagashima; Yuta Mukae; Kensuke Mistunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 2.  Role of the tumor immune microenvironment in tumor immunotherapy.

Authors:  Changsheng Zhou; Qianqian Liu; Yi Xiang; Xin Gou; Wengang Li
Journal:  Oncol Lett       Date:  2021-12-20       Impact factor: 2.967

Review 3.  Integrin-Mediated Tumorigenesis and Its Therapeutic Applications.

Authors:  Qingling Li; Ting Lan; Jian Xie; Youguang Lu; Dali Zheng; Bohua Su
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

4.  HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.

Authors:  Yizhou Zhang; Hanrong Li; Chao Lv; Baokang Wu; Yang Yu; Chongli Zhong; Qi Lang; Zhiyun Liang; Yang Li; Yu Shi; Jian Zhang; Feng Xu; Yu Tian
Journal:  Int J Oncol       Date:  2022-08-03       Impact factor: 5.884

5.  Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer.

Authors:  Marie Pariollaud; Lara H Ibrahim; Emanuel Irizarry; Rebecca M Mello; Alanna B Chan; Brian J Altman; Reuben J Shaw; Michael J Bollong; R Luke Wiseman; Katja A Lamia
Journal:  Sci Adv       Date:  2022-09-28       Impact factor: 14.957

6.  Pan-Cancer Analysis of the Prognostic and Immunological Role of HSF1: A Potential Target for Survival and Immunotherapy.

Authors:  Fei Chen; Yumei Fan; Pengxiu Cao; Bing Liu; Jiajie Hou; Bo Zhang; Ke Tan
Journal:  Oxid Med Cell Longev       Date:  2021-06-18       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.